This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Bausch Health" – news · newspapers · books · scholar · JSTOR(May 2018) (Learn how and when to remove this message)
This article may contain an excessive amount of intricate detail that may interest only a particular audience. Please help by spinning off or relocating any relevant information, and removing excessive detail that may be against Wikipedia's inclusion policy.(February 2023) (Learn how and when to remove this message)
(Learn how and when to remove this message)
Bausch Health Companies Inc.
Company type
Public
Traded as
TSX: BHC
S&P/TSX 60 component
ISIN
CA0717341071
Industry
Pharmaceuticals
Founded
1959; 65 years ago (1959) (as ICN Pharmaceuticals)
Founder
Milan Panić
Headquarters
Laval, Quebec, Canada
Key people
Thomas J. Appio (CEO) John Paulson (Chairman) Thomas G. Vadaketh (Executive VP & CFO) John S. Barresi (Senior VP & Controller)
Revenue
US$8.12 billion (2022)
Operating income
US$454 million (2022)
Net income
US$−212 million (2022)
Total assets
US$29.20 billion (2021)
Total equity
US$−34 million (2021)
Number of employees
c. 19,600 (2021)
Subsidiaries
Bausch & Lomb
Medicis Pharmaceutical
OraPharma
Salix Pharmaceuticals
Solta Medical
Website
bauschhealth.com
Footnotes / references [1]
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.[2]
Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Securities and Exchange Commission, causing its stock price to plummet more than 90 percent from its peak, while its debt surpassed $30 billion. In July 2018, the name of the company was changed to Bausch Health Companies Inc., in order to distance itself from the public outrage associated with massive price increases introduced by Valeant. At the same time, a new ticker symbol, BHC replaced VRX.[3]
^"Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results". Accesswire. 23 February 2023.
^Sagonowsky, Eric (August 16, 2019). "Bausch may have shed the Valeant name, but it still leans on price hikes: analyst". Fiercepharma.com.
^"Valeant, Distancing Itself From Its Past, Will Change Its Name to Bausch Health". The New York Times. 2018-05-08. ISSN 0362-4331. Retrieved 2018-05-08.
gastrointestinal disorders, eye health and neurology. BauschHealth owns Bausch & Lomb, a supplier of eye health products. BauschHealth's business model is primarily...
original on 26 January 2018. Retrieved 16 December 2019. Linnane C. "BauschHealth stock soars 8.6% premarket on news of patent settlement". MarketWatch...
2021, Valeant discontinued the product, and BauschHealth became the sole supplier of Seconal. BauschHealth stopped manufacturing the product in January...
biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including...
Corporation since July 1, 2010, Motricity since January, 2010, BauschHealth since March 2021 and Bausch + Lomb Corporation since June 2022. He also serves on...
(efinaconazole) Topical Solution, 10%, In Patients As Young As Six Years Old". BauschHealth (Press release). Archived from the original on 10 June 2022. Retrieved...
Regeneron (United States) for Macular degeneration (AMD) treatment and BauschHealth (Canada) for Front of eye. Following are examples of examination methods...
Tasmar (tolcapone), for parkinson's disease, licensed by Mylan and BauschHealth. Tecentriq (atezolizumab), for non-small cell lung cancer. TNKase (tenecteplase)...
Bristol-Myers Squibb. Cardizem (Diltiazem), for hypertension, Now owned by BauschHealth. Cholestagel (Colesevelam), for low-calorie diet and exercise. Cordarone...
lenses The Cooper Companies: through its CooperVision Alcon BauschHealth: through its Bausch & Lomb subsidiary X-Cel Specialty Contacts; maker of Westcon...
Bridgewater, New Jersey Key people Mark McKenna (SVP) Carolyn J. Logan (fmr. CEO) Adam C. Derbyshire (fmr.CFO) Parent BauschHealth Website salix.com...
www.themedicinescompany.com. Archived from the original on 2015-07-17. "Our Locations | BauschHealth". www.valeant.com. Retrieved November 10, 2016....
October 1995, assigned to Current Assignee Corwood Laboratories Inc and BauschHealth Companies Inc. Kaspiaruk H, Chęcińska L (June 2022). "A comparison...
On September 28, 2010, Biovail merged with Valeant Pharmaceuticals (BauschHealth). The company retained the Valeant name and J. Michael Pearson as CEO...
company was acquired by Valeant Pharmaceuticals in 2010 and is now BauschHealth. In 2007, Melnyk purchased a controlling stake in the Canadian beauty...
01% halobetasol and 0.045% tazarotene as a lotion branded as Duobrii (BauschHealth). It is available as a generic medication. "Ultravate product monograph"...
Barrick Gold Basic materials Gold mining Toronto 1983 Gold extraction BauschHealthHealth care Pharmaceuticals Laval 1960 Specialty pharmaceuticals BBC Kids...
language". Left's 2015 report on Valeant Pharmaceutical (later known as BauschHealth) accused the company of channel stuffing and using sham transactions...
manufacturers from foreign competition. Canada hosts several large public (BauschHealth) and private (Apotex) pharmaceutical companies as well as many subsidiaries...
200 countries. Those customers include Bausch & Lomb, Heineken, Wyndham Hotels, Boskalis, EBSCO, Legacy Health and Best Western International. Infor was...
Global Information
